10 Biggest Price Target Changes For Friday
Barclays lowered Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) price target from $302 to $285. Vertex Pharmaceuticals shares fell 13.3% to $187.88 in pre-market trading.
JP Morgan Downgrades MorphoSys to Neutral, Lowers Price Target to $24
JP Morgan analyst James Gordon downgrades MorphoSys (NASDAQ:MOR) from Overweight to Neutral and lowers the price target from $32 to $24.
Incyte, MorphoSys Announce 3-Year Results From Phase 2 L-MIND Study Of Tafasitamab In Combination With Lenalidomide For Treatment Of Relapsed Or Refractory DLBCL
-- Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Incyte (NASDAQ:INCY) and MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG ((FSE:
Bryan Garnier Downgrades MorphoSys to Neutral
Bryan Garnier analyst Victor Floc'h downgrades MorphoSys (NASDAQ:MOR) from Buy to Neutral.
SVB Leerink Upgrades MorphoSys to Outperform
SVB Leerink analyst Geoffrey Porges upgrades MorphoSys (NASDAQ:MOR) from Market Perform to Outperform.
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune’s Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 2)
Mid-Afternoon Market Update: Constellation Pharmaceuticals Surges Following Acquisition News; Protalix BioTherapeutics Shares Slide
Toward the end of trading Wednesday, the Dow traded up 0.05% to 34,594.18 while the NASDAQ fell 0.16% to 13,715.08. The S&P also rose, gaining 0.02% to 4,202.76.